The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
RNAi therapeutics: a potential new class of pharmaceutical drugs
Open accessAbstract
The rapid identification of highly specific and potent drug candidates continues to be a substantial challenge with traditional pharmaceutical approaches. Moreover, many targets have proven to be intractable to traditional small-molecule and protein approaches. Therapeutics based on RNA interference (RNAi) offer a powerful method for rapidly identifying specific and potent inhibitors of disease targets from all molecular classes. Numerous proof-of-concept studies in animal models of human disease demonstrate the broad potential application of RNAi therapeutics. The major challenge for successful drug development is identifying delivery strategies that can be translated to the clinic. With advances in this area and the commencement of multiple clinical trials with RNAi therapeutic candidates, a transformation in modern medicine may soon be realized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pulukuri, S. M., Gondi, C. S., Lakka, S. S., Jutla, A., Estes, N., Gujrati, M., & Rao, J. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503111200 · Cited by 285
RetractedPotent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 1×
“Starting from the discovery that RNAi is mediated by long double-stranded RNA in Caenorhabditis elegans by Fire and Mello in 199”
BackgroundLewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“Subsequent studies established that TLR-9, the receptor for unmethylated CpG-containing pathogen DNA, is the innate immune regulator engaged by antisense oligonucleotides 38 .”
BackgroundRNA interference is mediated by 21- and 22-nucleotide RNAs
Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,310
Asymmetry in the Assembly of the RNAi Enzyme Complex
Schwarz, D. S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., & Zamore, P. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00759-1 · Cited by 2,922
Functional siRNAs and miRNAs exhibit strand bias
Khvorova, A., Reynolds, A., & Jayasena, S. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00801-8 · Cited by 2,645
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Self-citation
Cited by
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
Bioconjugated quantum dots for in vivo molecular and cellular imaging☆
SMITH, A., DUAN, H., MOHS, A., & NIE, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.015 · Cited by 1,193
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery
Lee, H., Lytton-Jean, A. K. R., Chen, Y., Love, K. T., Park, A. I., Karagiannis, E. D., Sehgal, A., Querbes, W., Zurenko, C. S., Jayaraman, M., et al. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.73 · Cited by 1,169
Self-citationNair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Self-citationJackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Self-citationYao, J., Yang, M., & Duan, Y. (2014) · Chemical Reviews · doi:10.1021/cr200359p · Cited by 944
Cancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
Hybrid Molecules with a Dual Mode of Action: Dream or Reality?
Meunier, B. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000843 · Cited by 929
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Self-citationRNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
The origins and evolution of “controlled” drug delivery systems
Hoffman, A. S. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.08.012 · Cited by 738
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Self-citationsiRNA vs. shRNA: Similarities and differences
Rao, D. D., Vorhies, J. S., Senzer, N., & Nemunaitis, J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.004 · Cited by 660
siRNA delivery systems for cancer treatment
Oh, Y.-K., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 645
Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589
Therapeutic Antisense Oligonucleotides Are Coming of Age
Bennett, C. F. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041217-010829 · Cited by 579
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Molecular Mechanisms and Biological Functions of siRNA
Department of Biology, D. B., Dana, H., Chalbatani, G. M., Mahmoodzadeh, H., Gharagouzlo, E., Cancer Research Center, C. I. O. I., Karimloo, R., Department of Medicine, Z. M. S., Rezaiean, O., Moradzadeh, A., et al. (2017) · International Journal of Biomedical Science · doi:10.59566/ijbs.2017.13048 · Cited by 505
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500
“Although EGFR-TKIs are in wide clinical use for lung cancer (38), and inhibition of oncogenic miRNAs is a new promising approach in cancer therapy (39), this study reveals that the combination of these 2 therapeutic strategies can be significantly more effective than either alone.”
BackgroundA holistic approach to targeting disease with polymeric nanoparticles
Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4503 · Cited by 480
Multifunctional polymeric micelles for delivery of drugs and siRNA
Jhaveri, A. M., & Torchilin, V. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00077 · Cited by 466
Nonviral delivery of synthetic siRNAs in vivo
Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464
siRNA: Mechanism of action, challenges, and therapeutic approaches
Alshaer, W., Zureigat, H., Al Karaki, A., Al-Kadash, A., Gharaibeh, L., Hatmal, M. M., Aljabali, A. A. A., & Awidi, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174178 · Cited by 441
The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members
Farazi, T. A., Juranek, S. A., & Tuschl, T. (2008) · Development · doi:10.1242/dev.005629 · Cited by 435
Chen, D., Love, K. T., Chen, Y., Eltoukhy, A. A., Kastrup, C., Sahay, G., Jeon, A., Dong, Y., Whitehead, K. A., & Anderson, D. G. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301621z · Cited by 424
Proton-Sponge Coated Quantum Dots for siRNA Delivery and Intracellular Imaging
Yezhelyev, M. V., Qi, L., O’Regan, R. M., Nie, S., & Gao, X. (2008) · Journal of the American Chemical Society · doi:10.1021/ja800086u · Cited by 407
Development of a novel endosomolytic diblock copolymer for siRNA delivery
Convertine, A. J., Benoit, D. S. W., Duvall, C. L., Hoffman, A. S., & Stayton, P. S. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.10.004 · Cited by 406
Applications of nanoparticles in ophthalmology
Diebold, Y., & Calonge, M. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.08.002 · Cited by 392
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice
Tomlins, S. A., Bjartell, A., Chinnaiyan, A. M., Jenster, G., Nam, R. K., Rubin, M. A., & Schalken, J. A. (2009) · European Urology · doi:10.1016/j.eururo.2009.04.036 · Cited by 381
Iwamoto, N., Butler, D. C. D., Svrzikapa, N., Mohapatra, S., Zlatev, I., Sah, D. W. Y., Meena, Standley, S. M., Lu, G., Apponi, L. H., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3948 · Cited by 377
Self-citationBellavia, D., Raimondo, S., Calabrese, G., Forte, S., Cristaldi, M., Patinella, A., Memeo, L., Manno, M., Raccosta, S., Diana, P., et al. (2017) · Theranostics · doi:10.7150/thno.17092 · Cited by 368
A review of nanocarriers for the delivery of small interfering RNA
Kesharwani, P., Gajbhiye, V., & Jain, N. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.068 · Cited by 368
Polymeric Delivery of Therapeutic Nucleic Acids
Kumar, R., Santa Chalarca, C. F., Bockman, M. R., Bruggen, C. V., Grimme, C. J., Dalal, R. J., Hanson, M. G., Hexum, J. K., & Reineke, T. M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00997 · Cited by 365
Ganesh, S., Iyer, A. K., Morrissey, D. V., & Amiji, M. M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.077 · Cited by 362
Peptide-based nanomaterials: Self-assembly, properties and applications
Li, T., Lu, X.-M., Zhang, M.-R., Hu, K., & Li, Z. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.09.029 · Cited by 351
Spinocerebellar ataxia: an update
Sullivan, R., Yau, W. Y., O’Connor, E., & Houlden, H. (2019) · Journal of Neurology · doi:10.1007/s00415-018-9076-4 · Cited by 349
Oncogene Knockdown via Active Loading of Small RNAs into Extracellular Vesicles by Sonication
Lamichhane, T. N., Jeyaram, A., Patel, D. B., Parajuli, B., Livingston, N. K., Arumugasaamy, N., Schardt, J. S., & Jay, S. M. (2016) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-016-0457-4 · Cited by 347
RNA modifications in physiology and disease: towards clinical applications
Delaunay, S., Helm, M., & Frye, M. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-023-00645-2 · Cited by 345
Eguchi, A., Meade, B. R., Chang, Y.-C., Fredrickson, C. T., Willert, K., Puri, N., & Dowdy, S. F. (2009) · Nature Biotechnology · doi:10.1038/nbt.1541 · Cited by 340
Therapeutic plasmid DNA versus siRNA delivery: Common and different tasks for synthetic carriers
Scholz, C., & Wagner, E. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.014 · Cited by 333
Sustained Small Interfering RNA Delivery by Mesoporous Silicon Particles
Tanaka, T., Mangala, L. S., Vivas-Mejia, P. E., Nieves-Alicea, R., Mann, A. P., Mora, E., Han, H.-D., Shahzad, M. M. K., Liu, X., Bhavane, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3931 · Cited by 316
Shukla, J. N., Kalsi, M., Sethi, A., Narva, K. E., Fishilevich, E., Singh, S., Mogilicherla, K., & Palli, S. R. (2016) · RNA Biology · doi:10.1080/15476286.2016.1191728 · Cited by 309
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Huang, Y. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.003 · Cited by 291
siRNA therapeutics: a clinical reality
Saw, P. E., & Song, E.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 291
New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles
Zaimy, M. A., Saffarzadeh, N., Mohammadi, A., Pourghadamyari, H., Izadi, P., Sarli, A., Moghaddam, L. K., Paschepari, S. R., Azizi, H., Torkamandi, S., et al. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.16 · Cited by 289
RNAi therapeutic and its innovative biotechnological evolution
Weng, Y., Xiao, H., Zhang, J., Liang, X.-J., & Huang, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.012 · Cited by 286
Chemical modification: the key to clinical application of RNA interference?
Corey, D. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33483 · Cited by 285
Sheddable Ternary Nanoparticles for Tumor Acidity-Targeted siRNA Delivery
Yang, X.-Z., Du, J.-Z., Dou, S., Mao, C.-Q., Long, H.-Y., & Wang, J. (2012) · ACS Nano · doi:10.1021/nn204240b · Cited by 284
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Janas, M. M., Schlegel, M. K., Harbison, C. E., Yilmaz, V. O., Jiang, Y., Parmar, R., Zlatev, I., Castoreno, A., Xu, H., Shulga-Morskaya, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02989-4 · Cited by 279
Self-citationShu, D., Li, H., Shu, Y., Xiong, G., Carson, W. E., Haque, F., Xu, R., & Guo, P. (2015) · ACS Nano · doi:10.1021/acsnano.5b02471 · Cited by 270
Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems
Su, S., & M. Kang, P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090837 · Cited by 259
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
Gulino, A. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23696 · Cited by 258
Matrices and scaffolds for DNA delivery in tissue engineering
De Laporte, L., & Shea, L. D. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.017 · Cited by 258
Nonviral methods for siRNA delivery
Gao, K., & Huang, L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800134q · Cited by 244
Lipid nanoparticle-mediated drug delivery to the brain
Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E. L., & S Manickam, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114861 · Cited by 187
MicroRNAs in neurodegenerative diseases and their therapeutic potential
Junn, E., & Mouradian, M. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.10.002 · Cited by 186
Extension of the crRNA enhances Cpf1 gene editing in vitro and in vivo
Park, H. M., Liu, H., Wu, J., Chong, A., Mackley, V., Fellmann, C., Rao, A., Jiang, F., Chu, H., Murthy, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05641-3 · Cited by 102
Liu, H.-A., Liu, Y.-L., Ma, Z.-Z., Wang, J.-C., & Zhang, Q. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5891 · Cited by 97
Exosomes and microRNAs: New potential therapeutic candidates in Alzheimer disease therapy
Iranifar, E., Seresht, B. M., Momeni, F., Fadaei, E., Mehr, M. H., Ebrahimi, Z., Rahmati, M., Kharazinejad, E., & Mirzaei, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27214 · Cited by 93
Emerging Therapies in Transthyretin Amyloidosis – A New Wave of Hope After Years of Stagnancy?
Müller, M. L., Butler, J., & Heidecker, B. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1695 · Cited by 74
Hydrophobic tagging-mediated degradation of Alzheimer's disease related Tau
Gao, N., Chu, T.-T., Li, Q.-Q., Lim, Y.-J., Qiu, T., Ma, M.-R., Hu, Z.-W., Yang, X.-F., Chen, Y.-X., Zhao, Y.-F., et al. (2017) · RSC Advances · doi:10.1039/c7ra05347a · Cited by 62
Lin, Q., Jin, C. S., Huang, H., Ding, L., Zhang, Z., Chen, J., & Zheng, G. (2014) · Small · doi:10.1002/smll.201303842 · Cited by 62
Wang, X., Sommerfeld, M. R., Jahn‐Hofmann, K., Cai, B., Filliol, A., Remotti, H. E., Schwabe, R. F., Kannt, A., & Tabas, I. (2019) · Hepatology Communications · doi:10.1002/hep4.1405 · Cited by 56
Polymeric micelles for siRNA delivery
Falamarzian, A., Xiong, X.-B., Uludag, H., & Lavasanifar, A. (2012) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(12)50004-3 · Cited by 25
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
High-throughput transfection of interfering RNA into a 3D cell-culture chip
Zhang, H., Lee, M., Hogg, M. G., Dordick, J. S., & Sharfstein, S. T. (2012) · Small · doi:10.1002/smll.201102205 · Cited by 16
Wang, Y., Deng, S., & Xu, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0066 · Cited by 10
A comprehensive analysis of the use of nucleoside analogues in RNA therapeutics
Kukushkina-Zvezdova, A. A., Zherebtsova, A. A., Telegina, D. V., Skvortsov, I. A., Ivanov, R. A., & Reshetnikov, V. V. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08083-4 · Cited by 3
“These non-natural analogues stabilize mRNA and suppress innate immune activation, thereby enhancing therapeutic potency [27– 29].”
Metadata
- Authors
- Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y.
- Venue
- Nature Chemical Biology
- Published
- 2006-12
- Volume
- 2
- Issue
- 12
- Pages
- 711-719
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2021905258
- Cited by
- 1,085
- References
- 79
- FWCI
- 20.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.